H.C. Wainwright Reiterates Their Buy Rating on EKSO BIONICS (EKSO)

By Ryan Adsit

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on EKSO BIONICS (EKSOResearch Report), with a price target of $12.00. The company’s shares closed last Thursday at $7.36.

According to TipRanks.com, Ramakanth is a 2-star analyst with an average return of 0.0% and a 35.1% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Corvus Pharmaceuticals, and Cellectar Biosciences.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for EKSO BIONICS with a $12.00 average price target.

See today’s analyst top recommended stocks >>

Based on EKSO BIONICS’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.47 million and GAAP net loss of $2.53 million. In comparison, last year the company earned revenue of $3.62 million and had a GAAP net loss of $6.55 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ekso Bionics Holdings, Inc. engages in the design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. It operates through the following business segments: EksoHealth, EksoWorks, and Other. The EksoHealth segment consists of the engineering, manufacture, and sale of exoskeletons for applications in the medical markets. The EksoWorks segment offers exoskeleton devices to allow able-bodied users to perform heavy duty work for extended periods. The company was founded on January 30, 2012 and is headquartered in Richmond, CA.